Company Profile
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of pulmonary arterial hypertension (PAH).
Contact Information
Investor Relations
LifeSci Advisors
Mike Moyer
Managing Director
T: 617-308-4306
mmoyer@lifesciadvisors.com
Company Contact
Inhibikase Therapeutics, Inc.
1000 N. West Street
Suite 1200
Wilmington, DE 19801
info@inhibikase.com